Rossello, XavierRodriguez-Sinovas, AntonioVilahur, GemmaCrisóstomo, VerónicaJorge, InmaculadaZaragoza Sánchez, CarlosZamorano, José L.Bermejo, JavierOrdóñez, AntonioBoscá, LisardoVázquez, JesúsBadimón, LinaSánchez-Margallo, Francisco M.Fernández-Avilés, FranciscoGarcia-Dorado, DavidIbáñez, Borja2020-01-162020-01-1620192045-2322http://hdl.handle.net/10641/1807Despite many cardioprotective interventions have shown to protect the heart against ischemia/ reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the “Cardioprotection Large Animal Platform” (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a prespecified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/journal articleopen access10.1038/s41598-019-56613-6